<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC7461398/results/search/drugs/results.xml">
  <result pre="NCT04310228 (Not Applicable) 2 CHLOROQUINE AND HYDROXYCHLOROQUINE The synthesis of" exact="chloroquine" post="(CQ) backs to 1943 in Germany. During World War"/>
  <result pre="disorders. In 1955, one important analogue of CQ known as" exact="hydroxychloroquine" post="(HCQ) was employed for the treatment of rheumatologic and"/>
  <result pre="the antiviral mechanism of HCQ and CQ. CQ, chloroquine; HCQ," exact="hydroxychloroquine" post="Based on Figure 3, they concluded that HCQ could"/>
  <result pre="outcome follow‐up, but the obtained results especially using HCQ with" exact="azithromycin" post="were useful and could open a new window to"/>
  <result pre="inhibitor which is rapidly metabolized in vitro. However, co‐administration with" exact="ritonavir" post="(RTV; an inhibitor of the cytochromeP450 3A isoenzyme) inhibits"/>
  <result pre="point of view, 75 (76%) patients received antiviral treatment, including" exact="oseltamivir" post="(75 mg every 12 hours, orally), 500 mg LPV, 500 mg RTV and"/>
  <result pre="500 mg LPV, 500 mg RTV and the intravenous administration of 0.25 g" exact="ganciclovir" post="for 3 to 14 days. Most patients were given antibiotic"/>
  <result pre="calculated by AutoDock Vina and RosettaCommons. Their results suggested that" exact="indinavir" post="and remdesivir possessed the best docking scores, and the"/>
  <result pre="et al. The diagnostic utility of multifocal electroretinography in detecting" exact="chloroquine" post="and hydroxychloroquine retinal toxicity. Am J Ophthalmol. 2019;206:132‐139.31078540 8CortegianiA,"/>
  <result pre="The diagnostic utility of multifocal electroretinography in detecting chloroquine and" exact="hydroxychloroquine" post="retinal toxicity. Am J Ophthalmol. 2019;206:132‐139.31078540 8CortegianiA, IngogliaG, IppolitoM,"/>
  <result pre="EinavS. A systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID‐19. J Crit Care. 2020;57:279‐283.32173110"/>
  <result pre="J Crit Care. 2020;57:279‐283.32173110 9SchrezenmeierE, DörnerT. Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:1‐12.31784724"/>
  <result pre="Rev Rheumatol. 2020;16:1‐12.31784724 10ColsonP, RolainJ‐M, LagierJ‐C, BrouquiP, RaoultD. Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID‐19. Int J Antimicrob"/>
  <result pre="COVID‐19. Int J Antimicrob Agents. 2020;55:105932.32145363 11GaoJ, TianZ, YangX. Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID‐19"/>
  <result pre="DaiS‐M, TongQ. COVID‐19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression. J Antimicrob Chemother. 2020;75:1667‐1670.32196083"/>
  <result pre="Antimicrob Chemother. 2020;75:1667‐1670.32196083 14GautretP, LagierJ‐C, ParolaP, et al. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID‐19: results of an open‐label"/>
  <result pre="Commun. 2020;11(1):1‐14.31911652 16OuedraogoHG, MatteelliA, SulisG, et al. Pharmacokinetics of plasma" exact="lopinavir" post="and ritonavir in tuberculosis–HIV co‐infected African adult patients also"/>
  <result pre="16OuedraogoHG, MatteelliA, SulisG, et al. Pharmacokinetics of plasma lopinavir and" exact="ritonavir" post="in tuberculosis–HIV co‐infected African adult patients also receiving rifabutin"/>
  <result pre="and ritonavir in tuberculosis–HIV co‐infected African adult patients also receiving" exact="rifabutin" post="150 or 300 mg three times per week. Ann"/>
  <result pre="Commun. 2020;526(2):381‐388. 32223926 23WangM, CaoR, ZhangL, et al. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in"/>
 </snippets>
</snippetsTree>
